Hypoxia response element (HRE) (HRE)

The Hypoxia Response Element (HRE) is a specific DNA sequence, typically containing the core motif 5'-RCGTG-3', located within the promoter or enhancer regions of genes regulated by Hypoxia-Inducible Factor 1 (HIF-1) (Wang & Semenza, 1993, PNAS). These sites are often situated within or adjacent to GC-rich regions, which are essential for the recruitment of the HIF-1α/HIF-1β heterodimer under low-oxygen conditions (Wenger et al., 2005, Science Signaling). Upon binding, HIF-1 initiates the transcription of over 100 genes involved in crucial processes such as angiogenesis (VEGF), glucose metabolism (GLUT1), and cell survival, which are frequently hijacked by cancer cells to thrive in hypoxic tumor microenvironments (Semenza, 2000, J Appl Physiol). Because of their central role in tumor progression, these DNA binding sites have emerged as therapeutic targets for small molecules like Mithramycin A and Echinomycin, which bind to the DNA to sterically block HIF-1 access (Kong et al., 2005, Cancer Res). However, the therapeutic window for such agents is often narrow due to the potential for off-target binding to other GC-rich regulatory elements, leading to significant systemic toxicity (Previdi et al., 2010, British Journal of Cancer). This lack of specificity can inhibit other essential transcription factors, such as Sp1, which also recognize GC-rich motifs (Previdi et al., 2010, British Journal of Cancer). Despite these challenges, targeting the HRE remains a compelling strategy for disrupting the adaptive response of solid tumors to hypoxia.

Other names

HIF-1 binding siteGC-rich DNA binding siteHIF-binding DNA sequenceHypoxia-inducible factor response elementGC-rich hypoxia response element

Small molecules bind to GC-rich DNA sequences within or adjacent to the hypoxia response element, sterically hindering the binding of the HIF-1 transcription factor complex and preventing gene expression (Kong et al., 2005, Cancer Res; Previdi et al., 2010, British Journal of Cancer).